XML 21 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Intangible assets
 6 Months Ended
Jun. 30, 2022
Text block [abstract]  
Intangible assets
8. Intangible assets
 
    
Acquired
development
programs
  
Cost
   
£’000
  
At January 1, 2022 and June 30, 2022
   
 
33,005
 
    
 
 
  
Accumulated revision to estimated value
         
At January 1, 2022
      (8,441 ) 
Revision to estimated value
      (448 ) 
    
 
 
  
At June 30, 2022
   
 
(8,889
) 
    
 
 
  
Net book value
         
At January 1, 2022
      24,564  
    
 
 
  
At June 30, 2022
   
 
24,116
 
    
 
 
  
The present value of the provision for deferred cash consideration relating to the agreement with AstraZeneca was reviewed at June 30, 2022 (see Note
10
). The change in the period due to changes in timelines or probability of contractual milestones being achieved was a decrease of £0.4 
million which was
recognized as a reduction of the intangible asset in line with our accounting policies.
During the period the Company did not revise the value of any other intangible assets (2021: £nil). As the intangible assets remain under development, no amortization charge has been recognized (2021: £nil).